Amphetamine Toxicity

Suzanne R. White

doi:10.1055/s-2002-20586

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2002; 23(1): 027-036
DOI: 10.1055/s-2002-20586

Amphetamine Toxicity

Suzanne R. White

Emergency Medicine and Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, and Children's Hospital of Michigan Regional Poison Control Center, Detroit, Michigan

Abstract

ABSTRACT

Amphetamine abuse is widespread and associated with significant health risk. The most commonly encountered amphetamines are methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy), and the ephedra alkaloids. Although each of these harbors unique toxicity, they similarly impact the cardiovascular and neurological systems in overdose. Other serious complications associated with amphetamine abuse include severe hyperpyrexia and hyponatremia. Secondary conditions such as rhabdomyolysis, disseminated intravascular coagulation (DIC), gastrointestinal (GI) bleeding, hepatic necrosis, and renal failure are common, especially in those with hyperthermia. Chronic abuse poses risk of vasculitis, neuropsychiatric abnormalities, and cardiomyopathy. In addition, there is a growing body of evidence that even recreational abuse of methamphetamine and MDMA may produce long-lasting damage to dopaminergic and serotonergic neurons. Management principles include adequate sedation, aggressive cooling, and the use of titratable agents in the management of cardiovascular abnormalities.

KEYWORD

Amphetamine - methamphetamine - MDMA - ecstasy - ephedrine - Ma Huang - ephedra

Full Text

References

REFERENCES

1 Myerson A. Effect of benzedrine sulfate on mood and fatigue in normal and neurotic persons. Arch Neurol Psychiatry . 1936; 36 816-822
2 Heischober B, Derlet R W. Update on methamphetamine abuse. West J Med . 1989; 151 70-71
3 FDA Proposed Rules: Dietary Supplements Containing Ephedrine Alkaloids. Federal Register June 4, 1997 62(7): 30677-30724
4 Lesch K P, Heils A, Riederer P. The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenrative processes. J Mol Med . 1996; 74 365-78
5 Leonarid E T, Azmitia E C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology . 1994; 10 231-238
6 Liechti M E, Baumann C, Gamma A, Vollenweider F X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ``Ecstasy'') are attenuated by the serotonin uptake inhibitor Citalopram. Neuropsychopharmacol . 2000; 22 513-521
7 Zalia E C, Parmly L F. Fatal amphetamine poisoning. Arch Intern Med . 1963; 112 822-836
8 Demirkiran M, Jankovic J, Dean J M. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol . 1996; 19 157-164
9 Rella J G, Nelson L S, Hoffman R S. Seven years of 3,4-methylenedioxymethamphetamine (MDMA) toxicity. IJMT . 2000; 3(5) 28
10 US FDA Center for Food Safety and Applied Nutrition. Office of Special Nutritionals SN/AEMS
11 Haller C A, Benowitz N L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New Eng J Med . 2000; 343 1833-1838
12 Theoharides T. Sudden death of a healthy college student related to ephedrine toxicity from a Ma Huang-containing drink. J Clin Psychopharmacol . 1997; 17(5) 437-439
13 Anonymous. Adverse events associated with ephedrine-containing products-Texas, December 1993-September 1995. JAMA . 1996; 276(21) 1711-1712
14 Backer R, Tautman D, Lowry S. Fatal ephedrine intoxication. J Forensic Sciences . 1997; 42 157-159
15 Gaultieri J, Harris C. Dilated cardiomyopathy in a heavy ephedrine abuser. J Toxicol Clin Toxicol . 1996; 34 581-582
16 Zahn K A, Li R L, Purssell R A. Cardiovascular toxicity after ingestion of ``herbal ecstacy''. J Emerg Med . 1999; 17 289-291
17 Bruno A, Nolte K B, Chapin J. Stroke associated with ephedrine use. Neurology . 1993; 43 1313-1316
18 Herrideg C F, Brook M F. Ephedrine psychosis. BMJ . 1968; 2 160
19 Capwell R R. Ephedrine-induced mania from an herbal diet supplement. Am J Psychiatry . 1995; 152(4) 647
20 Wooten M R, Khangure M S, Murphy M J. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. Ann Neurol . 1983; 13 337-340
21 Adverse events with Ephedra and other botanical dietary supplements. FDA Medical Bulletin . 1994; 24 3
22 Powell T. Ma-Huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis . 1998; 32 153-159
23 Catlin D H, Sekera M, Adelman D C. Erythroderma associated with ingestion of an herbal product. Western J Med . 1993; 159(4) 491-493
24 Nadir A, Agrawal S, King P D. Acute hepatitis associated with the use of a chinese herbal product, Ma Huang. Am J Gastroenterol . 1996; 91 1436-1438
25 Blumenthal M, King P. A review of the botany, chemistry, medicinal uses, safety concerns, and legal status of ephedra and its alkaloids. Herbal Gram . 1995; 334 22-57
26 Woods J D, Henry J A. Hyperpyrexia induced by 3,4-methylenedioxymethamphetamine (``Ecstasy''). Lancet . 1992; 340 305
27 Logan Ast C, Stickle B, O'Keefe N, Hewitson H. Survival following ``Ecstasy'' ingestion with a peak temperature of 42°C. Anaesthesia . 1993; 48 1017-1018
28 Kolecki P. Inadvertent methamphetamine poisoning in pediatric patients. Ped Emerg Care . 1998; 14 385-387
29 Weinmann W, Bohnert M. Lethal monointoxication by overdosage of MDEA. Forensic Sci Int . 1998; 91(2) 91-101
30 Hall A P. Ecstasy and the anaesthetist. Br J Anaesth . 1997; 79 697-698
31 Colado M I, Williams J L, Green A R. The hyperthermic and neurotoxic effects of ecstasy (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol . 1995; 115 1281-1289
32 Mas M, Farre M, de la Torre R. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther . 1999; 290 136-145
33 Vollenweider F X, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (``ecstasy'') in MDMA-naïve healthy volunteers. Neuropsychopharmacol . 1998; 19 241-251
34 Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart . 2000; 83 627-633
35 Davis G G, Swalwell C I. Acute aortic dissection and ruptured berry aneurysms associated with methamphetamine abuse. J Forensic Med . 1994; 39 1481-1485
36 Guharoy R, Medicis J, Chol S, Stalder B, Kusiowski K, Allen A. Methamphetamine overdose: experience with six cases. Vet Hum Toxicol . 1999; 41(1) 28-30
37 Furst S, Fallon S, Reznik G. Myocardial infarction after inhalation of methamphetamine. N Engl J Med . 1990; 323 1147-1148
38 Bashour T. Acute myocardial infarction resulting from amphetamine abuse: spasm thrombus interplay?. Am Heart J . 1994; 128 1237-1238
39 Citron B, Halperm M, McCarron M. Necrotising angiitis associated with drug abuse. N Eng J Med . 1970; 283 1003-1011
40 Hong R, Matsuyama E. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA . 1991; 265 1152-1154
41 Perez J A, Arsura E L, Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med . 1999; 17 469-471
42 Matthews G, White S R, Smolinske S C. Ephedrine-related stroke in a teenager. J Toxicol Clin Toxicol . 1996; 34 602
43 Kaku D A, Lowenstein D H. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med . 1990; 113 821-827
44 Matick H, Anderson D, Brumlik J. Cerebral vasculitis associated with oral amphetamine overdose. Arch Neurol . 1983; 40 253-254
45 Buxton N, McConachie N S. Amphetamine abuse and intracranial haemorrhage. J Roy Soc of Med . 2000; 93 472-477
46 Rothrock J F, Rubenstein R, Lyden P D. Ischemic stroke associated with methamphetamine inhalation. Neurology . 1988; 38 589-592
47 Bitsch A M, Thiel A, Rieckmann P, Prange H. Acute inflammatory CNS disease after MDMA (``ecstasy''). Eur Neurol . 1996; 36 328-329
48 Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Eng J Med . 1999; 340 1443
49 Nagorka A R, Bergeson P S. Infant methamphetamine toxicity posing as scorpion envenomation. Ped Emerg Care . 1998; 14 350-351
50 Rhee K, Albertson T, Douglas J. Choreoathetoid disorders associated with amphetamine-like drugs. Am J Emerg Med . 1988; 6 131-133
51 White S R, Obradovic T, Imel K M, Wheaton M J. The effects of methylenedioxymethamphetamine (MDMA, ``ecstasy'') on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol . 1996; 49 455-479
52 Morgan M J. Memory deficits associated with recreational use of ``ecstasy''(MDMA). Psychopharmacol . 1999; 141 30-36
53 McCann U D, Mertl M, Eligulashvili V, Ricaurte G A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, ``ecstasy'') users: a controlled study. Psychopharmacology . 1999; 143 417-425
54 Bolla K I, McCann U D, Ricaurte G A. Memory impairment in abstinent MDMA (``Ecstasy'') users. Neurology . 1998; 51 1532-1537
55 McGuire P. Long-term psychiatric and cognitive effects of MDMA use. Toxicol Lett . 2000; 112-113 153-156
56 Kelly P A. Does recreational ecstasy use cause long-term cognitive problems?. West J Med . 2000; 173 129-130
57 Jansen K L. Ecstasy (MDMA) dependence. Drug Alcohol Depend . 1999; 53(2) 121-124
58 Fischer C, Hatzidimitirou G, Wlos J, Katz J, Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to recreational drug (+/-) 3,4-methylenedioxymethamphetamine (MDMA, ``Ecstasy''). J Neurosci . 1995; 15 5476-5485
59 Ricaurte G A, DeLanney L E, Irwin I, Langston J W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res . 1988; 446 165-168
60 Ricaurte G A, Forno L S, Wilson M A. (+/-) 3,4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA . 1988; 260 51-55
61 Ricaurte G A, Martello A L, Katz J L, Martello M B. Lasting effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharamcol Exp Ther . 1992; 261 616-622
62 Hatzidimitriou G, McCann U D, Ricaurte G A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neuroscience . 1999; 19 5096-5107
63 Kuhn D M, Geddes T J. Molecular footprints of neurotoxic amphetamine action. Ann NY Acad Sci . 2000; 914(12) 92-103
64 Ricaurte G A, Seiden L S, Schuster C R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Research . 1984; 303 359-364
65 Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden L S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther . 1987; 241 338-345
66 Obradovic T, Imel K M, White S R. Repeated exposure to methylenedioxymethamphetamine(MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin. Brain Res . 1998; 785 1-9
67 McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A. Positron emission tomographic evidence of toxic effect of MDMA (``Ecstasy'') on brain serotonin neurons in human beings. Lancet . 1998; 352 1433-1477
68 Kish S J, Furukawa Y, Ang L, Vorce S P, Kalasinski K S. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology . 2000; 55(2) 294-296
69 Obrocki J, Buchert R, Vaterlein O. Ecstasy long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry . 1999; 175 186-188
70 Chang L, Crob C S, Ernst T. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psych Research . 2000; 98 15-28
71 Reneman L, Booij J, Schmand B, Van den Brink W, Gunning B. Memory disturbances in ``Ecstasy'' users are correlated with an altered brain serotonin neurotransmission. Psychopharmacol . 2000; 148 322-324
72 Ernst T, Chang L, Leonido-Lee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology . 2000; 54 1344-1349
73 Vollenweider F X, Gamma A, Liechti M, Huber T. Is a single dose of MDMA harmless?. <~>(letter). Neuropsychopharmacology . 1999; 21 598-600
74 Holmes S B, Banerjee A K, Alexsander W D. Hyponatraemia and seizures after ecstasy use. Postgrad Med J . 1997; 5 32-33
75 Holden R, Jackson M A. Near fatal hyponatraemic coma due to vasopressin oversecretion after ``Ecstasy'' 3,4-methylenedioxymethamphetamine (MDMA). Lancet . 1996; 347 1052
76 Kessel B. Hyponatraemia after ingestion of ``ecstasy''. BMJ . 1994; 308 414
77 Parr M J, Low H M, Botterill P. Hyponatraemia and death after ``ecstasy'' ingestion. MJA . 1997; 166 136-137
78 Satchell S C, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatine kinase following MDMA ingestion. Br J Hosp Med . 1994; 51 495
79 Henry J A, Fallon J K, Kicman A, Hutt A J, Cowan D A, Forsling M. Low dose MDMA (``ecstasy'') induces vasopressin secretion. Lancet . 1998; 351 1784
80 Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Academic Emerg Med . 1998; 5(8) 839-840
81 O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B. Death from hyponatraemia-induced cerebral oedema associated with MDMA (``ecstasy'') use. NZ Med J . 1999; 112 255-256
82 Henry J A. Metabolic consequences of drug misuse. British J Anaesthesia . 2000; 85 136-142
83 Albertson T E, Walby W F, Derlet R W. Stimulant-induced pulmonary toxicity. Chest . 1995; 108 1140-1149
84 McCann U D, Seiden L S, Rubin L J, Ricaurte G A. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: a systematic review of the evidence. JAMA . 1997; 278 666-672
85 Ahmed J M, Salame M Y, Oakley G D. Chest pain in a young girl. Postgrad Med J . 1998; 74 115-116
86 Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology . 1999; 29 1347-1351
87 Andreu V, Mas A, Bruguera M. Ecstasy: a common cause of severe acute hepatotoxicity. J hepataology . 1998; 29 394-397
88 Ellis A J, Wendon J A, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut . 1996; 38 454-458
89 Scully R E, Mark E J, McNeely W F. Case records of the Massachusetts General Hospital. N Engl J Med . 2001; 344 591-599
90 Fidler H, Dhillon A, Gertner D, Burroughs A. Chronic ecstasy (3,4-methylenedioxymethamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol . 1996; 25 563-566
91 Johnson T D, Berenson M M. Methamphetamine-induced ischemic colitis. J Clin Gastroenterol . 1991; 13 681-689
92 Pecha R E, Prindiville T, Pecha B S, Camp R, Carroll M, Trudeau W. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gastroeneterol . 1996; 91 2523-2527
93 Richards J R, Johnson E B, Stark R W, Derlet R W. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med . 1999; 17 681-685
94 Murthy B VS, Wilkes R G, Roberts N B. Creatine kinase isoform changes following ecstasy overdose. Anaesth Intens Care . 1997; 25 156-159
95 Hall A P. Ecstasy: creatinine kinase. Anaesthesia and Int Care . 1997; 25 586-587
96 Foley R J, Kapatkin K, Verani R, Weinman E J. Amphetamine-induced acute renal failure. S Med J . 1984; 77 258-269
97 Woodrow G, Turney J H. Ecstasy-induced renal vasculitis. Nephrol Dial Transplant . 1999; 14 798
98 Marsh J C, Abboudi Z H, Gibson F M. Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine (``ecstasy''). Br J Haematol . 1994; 88 281-285
99 Bouchama A, Cafege A, Devol E B, Labdi O, El-Assil K, Seraj M. Ineffectiveness of dantrolene sodium in the treatment of heatsroke. Crit Care Med . 1991; 19 176-180
100 Derlet R W, Albertson T E, Rice P. Protection against d-amphetamine toxicity. Am J Emerg Med . 1990; 8 105-108
101 Richards J R, Derlet R W, Duncan D R. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med . 1998; 16 567-573
102 Dar K J, McBrien M E. MDMA induced hyperthermia: report of a fatality and review of current therapy. Int Care Med . 1996; 22(9) 995-996
103 Jones A L, Simpson K J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther . 1999; 13 129-133